Premium
Low‐Molecular‐Weight Heparins Are Essentially the Same for Treatment and Prevention of Venous Thromboembolism
Author(s) -
Lopez Larry M.
Publication year - 2001
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1592/phco.21.8.56s.34596
Subject(s) - medicine , venous thromboembolism , dose , pharmacodynamics , clinical trial , randomized controlled trial , low molecular weight heparin , anticoagulant , heparin , surgery , intensive care medicine , anesthesia , thrombosis , pharmacokinetics
The pharmacodynamic properties of low‐molecular‐weight heparins differ. Data from randomized clinical trials show that despite these differences, the agents have similar efficacy and safety profiles in preventing and treating new and recurrent venous thromboembolism in patients who underwent general surgery or total hip or knee replacement. Dalteparin, enoxaparin, or tinzaparin, when administered at the dosages used in the reviewed clinical trials, are essentially indistinguishable.